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Abstract
Background: The high affinity IgE receptor (FceRI) is a crucial structure for IgE-mediated allergic reactions. We have
previously demonstrated that human airway smooth muscle (ASM) cells express the tetrameric (abc2) FceRI, and its
activation leads to marked transient increases in intracellular Ca
2+ concentration, release of Th-2 cytokines and eotaxin-1/
CCL11. Therefore, it was of utmost importance to delineate the factors regulating the expression of FceRI in human (ASM)
cells.
Methodology/Principal Findings: Incubation of human bronchial and tracheal smooth muscle (B/TSM) cells with TNF-a, IL-
1b or IL-4 resulted in a significant increase in FceRI-a chain mRNA expression (p,0.05); and TNF-a, IL-4 enhanced the FceRI-a
protein expression compared to the unstimulated control at 24, 72 hrs after stimulation. Interestingly, among all other
cytokines, only TNF-a upregulated the FceRI-c mRNA expression. FceRI-c protein expression remained unchanged despite
the nature of stimulation. Of note, as a functional consequence of FceRI upregulation, TNF-a pre-sensitization of B/TSM
potentially augmented the CC (eotaxin-1/CCL11 and RANTES/CCL5, but not TARC/CCL17) and CXC (IL-8/CXCL8, IP-10/
CXCL10) chemokines release following IgE stimulation (p,0.05, n=3). Furthermore, IgE sensitization of B/TSM cells
significantly enhanced the transcription of selective CC and CXC chemokines at promoter level compared to control, which
was abolished by Lentivirus-mediated silencing of Syk expression.
Conclusions/Significance: Our data depict a critical role of B/TSM in allergic airway inflammation via potentially novel
mechanisms involving proinflammatory, Th2 cytokines and IgE/FceRI complex.
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Introduction
Airway inflammation has been considered as a critical factor in
the pathogenesis of allergic asthma, often associated with
bronchial hyperresponsiveness and is correlated with disease
severity [1]. The inflammation is mainly due to an increased
number of activated T lymphocytes, mast cells, eosinophils, and
neutrophils within the airway lumen and bronchial submucosa
[1,2]. The CD4
+ T cells have been demonstrated as the
predominant cell type involved in the regulation of airway
inflammation through the expression of T helper 2 (Th2) cytokines
[2].
Besides these prototype inflammatory cells, however, airway
smooth muscle (ASM) cells have been described recently as a rich
source of proinflammatory cytokines, chemokines, and growth
factors; and have been considered as key inflammatory determi-
nants of asthma pertaining to their ability to contract in response
to these mediators [3]. ASM cells can contribute directly to the
pathogenesis of asthma by expressing cell adhesion and co-
stimulatory molecules and by secreting multiple proinflammatory
cytokines and chemokines that may perpetuate airway inflamma-
tion and the development of airway remodeling in vivo [4].
Therefore, it is now widely accepted that ASM actively
participates in the pathogenesis of allergic asthma, by virtue of
its role in airway inflammation, airway hyperresponsiveness and
airway remodeling.
Several studies have led to novel insights into immune processes
and the role of IgE in atopic diseases such as asthma [5]. Bronchial
hyperresponsiveness has been shown to be associated with
increased serum IgE levels and could be transferred from
asthmatic to non-asthmatic subjects by IgE-rich serum adminis-
tration [5]. The biological activities of IgE are mediated through
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receptors [6,7]. Initially discovered on mast cells and basophils
which are involved in cellular degranulation, FceRI has been
shown to be expressed by many inflammatory cells including
Langerhans cells, dendritic cells, monocytes, eosinophils, platelets,
neutrophils from allergic asthmatics, and bronchial epithelial cells
[7,8]. Very recently, FceRI expression was detected in pinealo-
cytes, the melatonin-secreting cells of the pineal gland, where it is
proposed to provide a missing link between the neuroendocrine
and the immune system in context of the neural control of allergic
disorders [9].
Classically, TNF-a and IL-1b are prototype pro-inflammatory
cytokines, which have been shown to play a central role in lung
inflammation both in animal models and allergic patients
[10,11,12,13]. Th-2 cytokines are also known to play a critical
role in pathogenesis of allergic disorders, and have been
investigated extensively in strategies targeting respiratory diseases
[14]. In particular, IL-4, in combination with IL-13 is known to
induce Th-2 humoral immune responses leading to IgE produc-
tion by B-cells [6].
We have previously demonstrated that human ASM (HASM)
cells express the tetrameric (abc2) FceRI and its activation leads to
transient increases in intracellular Ca2
+ concentration, and release
of IL-4, IL-5, IL-13 and the CC chemokine eotaxin-1/CCL11
[15]. Taking into account the proinflammatory and Th-2 cytokine
milieu in allergic inflammation and expression of FceRI on ASM,
it was imperative to examine the factors regulating the expression
of FceRI in human ASM cells. FceRI-a-chain, a member of the
immunoglobulin superfamily, contains the binding site for its
ligand (IgE) while both b and c chains are responsible for the
downstream signal propagation through the phosphorylation of
their immunoreceptor tyrosine-based activation motif (ITAM) [7].
Here we demonstrate that TNF-a, IL-1b, and IL-4 induce the
FceRI-a mRNA and protein expression in human bronchial/
tracheal smooth muscle (B/TSM) cells. The functional studies
demonstrated that the IgE stimulation of cytokine pre-sensitized
B/TSM cells significantly augmented the selective CC and CXC
chemokine expression. Interestingly, Lentivirus mediated spleen
tyrosine kinase (Syk) silencing abrogated the IgE sensitization-
induced transcription of selective CC and CXC chemokines at
promoter level. Cumulatively, these results suggest the potentially
novel mechanisms of FceRI regulation, portraying the critical role
of B/TSM associated IgE/FceRI complex in allergic airway
inflammation.
Materials and Methods
Ethics statement
All the experimental procedures were approved by the Human
Research Ethics Board of the University of Manitoba, Winnipeg,
Manitoba, Canada. Written informed consent for ASM harvesting
was obtained from all patients.
Reagents
Recombinant human TNF-a, IL-1b and IL-4 were purchased
from R&D Systems (Minneapolis, MN, USA). Recombinant
human IgE was obtained from Diatec (BioPorto Diagnostics A/S,
Denmark). Murine anti-human FceRIa-chain mAb, 15/1 [16],
was kindly donated by Dr. Franz Kricek (NOVARTIS Institute
for Biomedical Research GmbH & Co KG, Vienna, Austria).
Fetal bovine serum (FBS), sodium pyruvate, trypsin were
purchased from HyClone (Logan, UT, USA). 100X L-glutamine,
DMEM, Ham’s F-12, trypsin-EDTA, and antibiotics (penicillin,
streptomycin) were purchased from Invitrogen Canada Inc.
(Burlington, ON, Canada). Plasmids encoding luciferase reporter
driven by respective wild-type chemokine promoters were kindly
gifted (pGL3-EO2 eotaxin-1/CCL11 pr by Dr. Jutta Horejs-
Hoeck, Institute for Chemistry and Biochemistry, Salzburg,
Austria; pUHC13-3-IL-8pr-wild type by Dr. Michael Kracht,
Medical School Hannover, Hannover, Germany; pGL3-
RANTES-Luc wild-type by Dr. Akira Andoh, Shiga University
of Medical Science, Seta-Tukinowa, Otsu 520-2192, Japan;
pGL3-IP-10 (-533) by Dr. Daniel A Muruve, University of
Calgary, Calgary, Alberta, Canada). Unless stated otherwise, all
other reagents were obtained from Sigma-Aldrich Canada Ltd.
(Oakville, ON, Canada).
Preparation of Human Bronchial/Tracheal Smooth
Muscle (B/TSM) Cells
Three sources of human airway smooth muscle cells were used.
Both hTERT immortalized and primary human bronchial smooth
muscle (HBSM) cells were prepared as described by us previously
[18,19]. Primary human tracheal smooth muscle (HTSM) cells
were obtained from macroscopically healthy segments of the
trachea during post-mortem in Respiratory Hospital at Health
Sciences Centre, Winnipeg, MB, Canada, and were isolated,
cultured as we used for primary HBSM cells [15,18,19]. At
confluence, primary B/TSM cells exhibited spindle morphology
and a hill-and-valley pattern that is characteristic of smooth
muscle in culture. Moreover, B/TSM cells at confluence retain
smooth muscle-specific actin, SM22, and calponin protein
expression and mobilize intracellular Ca2+ in response to
acetylcholine, a physiologically relevant contractile agonist [19].
In all the experiments, primary B/TSM cells were used at passages
2–5, and hTERT cells at passages 10–17.
Cell stimulation
Sub-confluent B/TSM cells were growth arrested and synchro-
nized by serum deprivation for 48 h in Ham’s F-12 medium
containing 5 mg/ml human recombinant insulin, 5 mg/ml human
transferrin, 5 ng/ml selenium, and antibiotics (100 U/ml penicil-
lin and 100 mg/ml streptomycin). Cells were then stimulated in
fresh FBS-free medium containing human recombinant IL-1b
(10 ng/ml), TNF-a (10 ng/ml), IL-4 (10 ng/ml), IgE (1 or 10 mg/
ml) or vehicle (medium alone) for time periods specific to
experiments, as mentioned below.
RNA isolation and RT-PCR
Serum-deprived confluent B/TSM cultures were harvested, and
total cellular RNA was extracted using TRIzolH method
(Invitrogen Canada Inc., Burlington, ON). Reverse transcription
was performed by using 2 mg of total RNA in a first-strand cDNA
synthesis reaction with High Capacity cDNA Reverse transcrip-
tase kit as recommended by the supplier (Applied Biosystems,
Foster City, CA, USA). Oligonucleotide primers were synthesized
on the basis of the entire coding region of human FceRI-a
(GenBank accession no. NM 002001.2) as follows: Forward
primer 59-CTCCATTACAAATGCCACAGTTG-39 and Re-
verse primer 59-CACGCGGAGCTTTTATTACAGTA-39; and
for human FceRI-c (GenBank accession no. NM004106) were:
Forward primer, 59-CCA GCA GTG GTC TTG CTC TTA C-39
and reverse primer, 59-GCA TGC AGG CAT ATG TGA TGC
C-39. Primers for human housekeeping gene, glyceraldhyde-3-
phosphate dehydrogenase (GAPDH) are forward primer 59-
AGCAATGCCTCCTGCACCACCAAC-39 and reverse primer
59-CCGGAGGGGCCATCCACAGTCT-39. The PCR (FceRI-
a, 35 cycles; FceRI-c, 30 cycles; GAPDH, 25 cycles) was
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Mississauga, ON). Each cycle included denaturation (94uC,
1 min), annealing (FceRI-a,5 9 uC, 1 min; FceRI-c,6 4 uC, 1 min
and; GAPDH, 55uC, 1 min), and extension (72uC, 1 min 30 s).
The initial denaturation period was 5 min, and the final extension
was 10 min. The size of the amplified FceRI-a,- c and GAPDH
fragment was 116 bp, 338 bp and 137 bp, respectively. GAPDH
was amplified as internal control. Amplified products were
analyzed by DNA gel electrophoresis in 1.5% agarose and
visualized by ethidium bromide staining under ultraviolet
illumination. The specificity of the amplified bands was confirmed
by nucleic acid sequencing (data not shown).
Real-time RT-PCR analysis
The FceRI-a and GAPDH standards were prepared using
PCR-amplified cDNA from a human basophilic cell line (KU812,
ATCCH # CRL-2099
TM). PCR products were isolated from 2%
w/v agarose gel using QIAEX II Agarose Gel Extraction kit
(Qiagen Inc., Mississauga, ON, Canada). The primers used were
same as we used for RT-PCR, as mentioned above. The amount
of extracted cDNA was quantified by spectrophotometry and
expressed as copy number. A serial dilution was used to generate
each standard curve. Real-time quantitative PCR was carried out
by ABI 7500 Real-Time PCR System and analyzed by 7500
System SDS software version 1.3.1 (Applied Biosystems, Foster
City, CA, USA), following manufacturer’s instructions. Product
specificity was determined by melting curve analysis and by
visualization of PCR products on agarose gels. Calculation of the
relative amount of each cDNA species was performed according to
standard protocols. Briefly, the amplification of FceRI-a gene in
stimulated cells was calculated first as the copy number ratio of
FceRI-a to GAPDH, and then expressed as normalized values of
fold increase over the value obtained with unstimulated (control)
cells.
Immunoprecipitation and Western blot
B/TSM FceRIa-chain protein expression was analyzed by
immunoprecipitation and Western blotting with minor modifica-
tions from the protocol described earlier [8]. Briefly, B/TSM cells
were lysed for 30 min 4uC in NP-40 lysis buffer supplemented with
a cocktail of protease inhibitors (2 mM sodium orthovanadate,
1 mM phenyl-methylsulfonylfluoride, 10 mg/ml leupeptin, 0.15
units/ml approtinin, 1 mg/ml pepstatin A) (Sigma-Aldrich) and
centrifuged for 20 min to remove nuclei. Cell lysates from B/TSM
or basophilic cell line KU812 (positive control) were pre-cleared
with protein G sepharose-coated beads (Amersham-Pharmacia) for
2 h at 4uC in a rotating mixer, followed by incubation with protein
G sepharose-coated beads conjugated with 2 mg/ml of murine
anti-human FceRIa mAb 15/1 or isotype mouse IgG1 monoclo-
nal antibody (MOPC 21) for 16 h at 4uC. Immuno-complexes
were then pelleted by centrifugation and washed six times with the
wash buffer (PBS/1% NP40). For immunoblotting, samples were
separated on SDS polyacrylamide gel (11–13%) and electro-
transferred onto PVDF membrane (Millipore, Mississauga, ON).
The membrane was blocked at RT for 2 hrs with 5% Blotto,
(Santa Cruz Biotechnology, CA, USA), incubated with rabbit anti-
human FceRIa-chain polyclonal Ab (Upstate Biotechnology, Inc.,
Lake Placid, NY) (1 mg/ml) at room temperature for 2 h, followed
by secondary antibody HRP-goat anti-rabbit IgG (H+L) prepared
in TBST (1:5000). The blots were developed by enhanced
chemiluminescence as recommended by the supplier (Amersham
Pharmacia, ON). A band non-specific to FceRI in the same gel
was used as loading control. On the other hand, 15 mg of B/TSM
and KU812 cell lysates were directly loaded onto 14% SDS
polyacrylamide gel (11–13%) and electro-transferred onto PVDF
membrane. The membrane was blocked at RT for 2 hrs with 5%
Blotto, incubated with goat anti-human FceRI-c polyclonal Ab
(K-16 clone) (Santa Cruz, CA) prepared in TBST (1:500) at RT
for 2 h, followed by secondary antibody HRP-rabbit anti-goat IgG
whole molecule (Sigma-Aldrich) prepared in TBST (1:5000), and
the blots were developed as described above. After stripping, the
blots were probed for GAPDH and used as a loading control. The
corresponding values of pre-stained protein molecular weight
marker were scaled to the FceRI-a and -c protein bands. The
intensity of FceRI-c bands was determined by using AlphaEase FC
software version 3.1.2 relative to control loading levels.
CC and CXC Chemokines ELISA from cytokine pre-
sensitized B/TSM cell supernatants
In order to study the functional significance of cytokine
stimulated FceRIa-chain upregulation, primary human B/TSM
cells were grown until 65% confluency in 12-well culture plates
and 48 h serum-deprived cells were then stimulated for 48 h with
recombinant human IL-1b, TNF-a, IL-4 (10 ng/ml each) or
vehicle (medium alone). The supernatants were removed and cells
were washed twice with serum-free Ham’s F12 media. Thereafter,
the cells in each treatment group were either left unstimulated
(medium alone) or stimulated with mIgG1 (1 mg/ml) or recom-
binant human IgE (1 mg/ml) for 24 h under the similar culture
conditions. The culture supernatants were then collected,
centrifuged at 1200 rpm for 7 min at 4uC to remove cellular
debris and stored at 280uC until future use. Immunoreactive
eotaxin-1/CCL11, IL-8/CXCL8, IP-10/CXCL10 (10 kDa inter-
feron-gamma-induced protein), RANTES/CCL5 (Regulated up-
on Activation, Normal T-cell Expressed, and Secreted), and
TARC/CCL17 (Thymus and activation-regulated chemokine)
released into B/TSM culture supernatants were quantified using
ELISA with matched Abs according to basic laboratory protocol
provided by the manufacturer (R&D Systems, Minneapolis, MN,
USA). Chemokine proteins were quantified in reference to serial
dilutions of recombinant standards falling within the linear part of
the standard curve for each specific chemokine sample measured.
The sensitivity limits of these chemokine assays are 5 pg/ml for
eotaxin-1/CCL11, 3 pg/ml for IL-8/CXCL8, 7.8 pg/ml for IP-
10/CXCL10, 7.8 pg/ml for RANTES/CCL5 and 7.8 pg/ml for
TARC/CCL17. Each data point represents readings from three
separate assays.
Lentiviral vector transduction in B/TSM cells
For short-hairpin RNA (shRNA)-induced gene silencing studies,
pseudotyped lentiviral vector (clone Id: V2LHS_153702) express-
ing specific Syk shRNA was obtained from Open-Biosystems
(Huntsville, AL). 293T cells used for virus production and titration,
were cultured in Iscove’s modified Dulbecco’s medium (HyClone,
Logan, UT) supplemented with 10% fetal bovine serum (FBS),
and 1% penicillin/streptomycin/glutamate (PSG) (Gibco, Grand
Island, NY). Lentivirus were generated using 293T cell lines and
viral titer was determined by counting the puromycin resistant
colonies, as described elsewhere [21]. A control shRNA unrelated
to Syk sequence (scramble shRNA) was used as a transduction
control. For silencing Syk protein expression, B/TSM cells were
transduced at a multiplicity of infection (MOI) of 10 in the
presence of polybrene (8 mg/ml). In brief, cells were exposed to
recombinant lentivirus for 2 hr at 37uC, medium replaced and
cultured for additional 72 hrs. Transduced cells were selected with
puromycin. The average transduction efficiency was more than
95% as determined by FACS using the turbo-green fluorescent
protein (tGFP) as the marker for cell sorting. Viability of the
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trypan blue dye after completion of the experiment.
Luciferase reporter constructs and cell transfection
Normal, Syk-silenced, and scramble-shRNA-transduced B/TSM
cells (4610
4) were plated into 12-well culture plates in fresh
complete DMEM. At 50–70% confluency, cells were transfected
with wild-type plasmid constructs containing promoters for human
eotaxin-1/CCL11, IL-8/CXCL8, IP-10/CXCL10 or RANTES/
CCL5. Transient transfection of B/TSM cells was performed using
ExGen 500 in vitro transfection reagent (MBI Fermentas, ON,
Canada) according to the manufacturer’s instructions. In each well,
1.6 mg of wild-type chemokine promoter DNA and 0.4 mgo fRenilla
luciferase reporter vector-pRL-TK (Promega, Madison, WI) were
co-transfected for 24 h. The medium was changed and cells were
washed and stimulated with human IgE (10 mg/ml), IL-1b (10 ng/
ml) or mouse IgG1 (mIgG1-MOPC21) (10 mg/ml). Since IL-1b is
known to induce multiple cytokines/chemokines gene expression in
human ASM cells [22,23,24,25], it was used as a positive control for
promoter activity assays. The luciferase activity was measured by
theDual-LuciferaseAssaySystemkit(Promega,Madison,WI)using
a luminometer (model LB9501; Berthold Bad Wildbad, Germany).
Briefly, 20 ml of cell lysate was mixed with 100 ml of Luciferase
Assay Reagent II and firefly luciferase activity was first recorded.
Then, 100 ml of Stop-and-Glo Reagent was added, and Renilla
luciferase activity was measured. All values were normalized to
Renilla luciferase activity and expressed relative to the control
transfected non-stimulated cells.
Statistical analysis
All the data were obtained from experiments performed three or
more times. Statistical analysis was performed by using GraphPad
Prism Software Version 3.02 for Windows (GraphPad Software
Software, San Diego, CA, USA). Association between chemokine
expression levels in the subgroups and cytokine stimulation effect on
FceRI expression were studied using Mann-Whitney U test. P
values ,0.05 were considered statistically significant.
Results
TNF-a, IL-1b, and IL-4 regulate the FceRI-a chain mRNA
Expression in Human B/TSM cells
We previously speculated the probable modulation of FceRI
expression in ASM cells by proinflammatory and Th2 cytokines
Figure 1. Proinflammatory and Th-2 cytokines upregulate the FceRI mRNA expression in human B/TSM cells. Human B/TSM FceRI-a
and –c mRNA expression was analysed by (A) RT-PCR and (B) by Real-time RT-PCR for FceRI-a chain. GAPDH was used as internal control for (A) and to
normalize the FceRI-a copy number for (B) as described in Materials and Methods. Each data point (except for TNF-a at 6 h) represents a significant
(p,0.05, n=3) increase in copy no. over unstimulated control. P values were calculated using Mann Whitney U test.
doi:10.1371/journal.pone.0006153.g001
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IL-1b, TNF-a, or IL-4 showed significantly enhanced FceRI-a
mRNA expression (Figure 1A). In contrast to cytokine stimulation,
the basal FceRI-a mRNA expression was uniform and unaffected
by time of culture. FceRI-a mRNA increased expression was then
confirmed by quantitative real-time RT-PCR analysis. As shown
in Figure 1B, B/TSMCs stimulated with TNF-a, and IL-1b
upregulated the FceRI-a transcript expression by 45.064.5-, and
28.263.8-fold, respectively, compared to unstimulated cells at 2 h.
Interestingly, the mRNA expression was downregulated at 6 h but
again gained peak at 20 h; whereas TNF-a inducing the
maximum expression (32.462.1-fold). Notably, IL-4 stimulation
steadily upregulated the FceRI-a mRNA expression (2.4460.28-
fold, 2 h; 2.4360.29-fold, 6 h; and 2.7960.7-fold, 20 h) compared
to the control in B/TSM cells (Figure 1B). On the other hand, the
mRNA expression for FceRI-c chain was upregulated by TNFa
only at 2 h (Figure 1A). Collectively, this data suggest that
proinflammatory and Th-2 cytokines can potentially regulate the
transcription of FceRI in B/TSM cells.
TNF-a, IL-4 upregulate the FceRI-a protein expression in
human B/TSMCs
To investigate the effect of IL-1b, TNF-a, and IL-4 stimulation
on FceRI-a and -c protein expression, serum-deprived B/TSM
cells were stimulated with TNF-a, IL-1b, or IL-4 and subjected to
immunoprecipitation and Western blot. As demonstrated in
Figure 2A, TNF-a and IL-4 stimulation enhanced the ,45 KDa
(referred to be the intracellular) [7,8] FceRI-a protein expression
at 24 h compared to unstimulated or IL-1b-stimulated B/TSMCs.
Immunoprecipitation from basophilic cell line KU812 also
revealed a positive band at ,45 KDa (Figure 2A).
We then explored the effect of chronic (72 h) cytokine
stimulation on FceRI-a protein expression. As shown in
Figure 2B, TNF-a, and IL-4 stimulation for 72 h led to the
upregulation of FceRI-a protein in B/TSM cells. TNF-a
stimulation remarkably augmented the ,45 KDa intracellular
and 60–65 KDa (referred to be as surface chain) [27] FceRI-a
protein compared to unstimulated B/TSM cells (Figure 2B).
Chronic IL-4 stimulation also augmented the FceRI-a protein
expression, both for ,45 KDa and ,60–65 KDa bands
(Figure 2A and B). In contrast to FceRI-a and TNF-mediated
FceRI-c mRNA upregulation, no significant upregulation in
protein was observed (Figure 2C and D). As expected, KU812
cell lysate revealed both FceRIa intracellular and surface, and
FceRI-c protein bands and served as a positive control.
Importantly, immunoprecipitation with isotype control antibody
mIgG1-MOPC21 did not show any conspicuous bands of FceRI-a
either of ,45 KDa or 60–65 KDa at 24 or 72 h stimulation.
Collectively, our data demonstrate that TNF-a and IL-4
upregulate the FceRI-a chain protein expression in B/TSM cells.
TNF-a pre-sensitization augments the eotaxin-1/CCL11,
IL-8/CXCL8, IP-10/CXCL10, RANTES/CCL5 but not TARC/
CCL17 release in B/TSM following IgE stimulation
We then investigated the functional consequences of FceRI-a
protein upregulation by TNF-a, or IL-4 in B/TSM cells. Since we
have previously demonstrated that IgE-dependent activation of B/
TSM cells induces the CCL11 release [15], it was enticing to assess
whether TNF-a or IL-4-mediated FceRI-a protein upregulation
followed by IgE stimulation can augment the chemokines release
by B/TSM cells. Therefore, B/TSM cells were first sensitized with
TNF-a, IL-1b, or IL-4 for 48 h, washed and then stimulated with
IgE, mIgG1 (MOPC21) or left unstimulated for 24 h in fresh
medium. CC (CCL11, CCL5, and CCL17) and CXC (CXCL8
and CXCL10) chemokines released in supernatants were then
measured by ELISA. Since IL-1b did not induce a marked FceRI-
a protein expression (Figure 2A and B), it is plausible that it would
not affect the subsequent chemokine release following IgE
stimulation. Interestingly, TNF-a pre-sensitized B/TSM cells
released significantly elevated (p,0.05, n=3) levels of eotaxin-
1/CCL11, IL-8/CXCL8, IP-10/CXCL10, and RANTES/CCL5
following IgE stimulation compared to IgE-unstimulated cells
(Figure 3A, B, C and D). Moreover, IL-4 pre-sensitization followed
by IgE stimulation also enhanced the eotaxin-1/CCL11 release
significantly (p,0.01, n=3, Figure 3A). We, however, did not see
any significant change in TARC/CCL17 release in TNF-a, IL-1b,
or IL-4 pre-sensitized and IgE stimulated B/TSM cells (data not
shown), suggesting the selective nature of FceRI activation-
induced chemokine expression. These results, therefore, suggest
that TNF-a, in particular, upregulates the FceRI-a expression as
considerably that subsequent stimulation of B/TSM with IgE
engages and activates the FceRI strongly, leading to enhanced
selective chemokine release.
IgE sensitization induces eotaxin-1/CCL11, IL-8/CXCL8, IP-
10/CXCL10, and RANTES/CCL5 promoter activation in B/
TSM cells
To unravel the mechanism by which IgE engagement of FceRI
on cytokine pre-sensitized B/TSM leads to enhanced CC and
CXC chemokine release, we then tested whether IgE alone can
induce promoter activity of CCL11, CXCL8, CXCL10 and
CCL5 in B/TSM cells. B/TSM cells were transiently transfected
with the luciferase reporter constructs driven by respective wild-
type chemokine promoters. As shown in Figure 4, IgE stimulation
of B/TSM cells significantly enhanced the promoter activity of
eotaxin-1/CCL11, 1.4260.13-fold; IL-8/CXCL-8, 1.4660.11-
fold; IP-10/CXCL10, 1.3360.05-fold; and RANTES/CCL5,
1.3260.09-fold, (n=3 p,0.05) compared to the unstimulated
control. Murine isotype mIgG1 (MOPC21) stimulation failed to
induce the promoter activity for any of the chemokines tested.
Furthermore, as reported earlier in structural cells including
ASMC [22,23,24,25], IL-1b stimulation strongly induced the
promoter activity of eotaxin-1/CCL11, 2.1760.17-fold; IL-8/
CXCL-8, 3.2660.30-fold (n=3, p,0.01); IP-10/CXCL10,
1.6560.03-fold; and RANTES/CCL5, 1.4960.02-fold, (n=3,
p,0.05) compared to the unstimulated control (Figure 4).
Altogether, these results demonstrate that the IgE induces CC
and CXC chemokine gene expression in B/TSM cells by acting at
least at the promoter level.
Lentivirus mediated Syk-silencing abrogates the IgE-
induced transcriptional activation of human eotaxin-1/
CCL11, IL-8/CXCL8, IP-10/CXCL10, and RANTES/CCL5
promoters in B/TSM cells
In the light of the above findings, we further investigated
whether IgE-induced chemokine expression involved the FceRI
activation. In inflammatory cells such as mast cells, FceRI
activation triggers many signaling pathways including the
phosphorylation of FceRI-b and -c by Lyn kinase, followed by
the activation of Syk through its recruitment to FceRI [7].
Activation of Syk is crucial for FceRI downstream signals
propagation including phosphorylation of phospholipase Cc,
calcium mobilization, degranulation, and proinflammatory cyto-
kine/chemokine release [7,26]. These observations suggest that
blocking/silencing the Syk expression might be a useful strategy to
investigate the FceRI activation in B/TSM cells. To inhibit the
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lentiviral vector expressing specific Syk-shRNA. Mock and
scramble sequence were used as negative controls. As shown in
Figure 5A, more than 95% of the lentivirus-transduced cells were
tGFP positive by FACS analysis. Transduction of cells with Syk-
shRNA clone resulted in a highly significant and reproducible
decrease in Syk expression, as shown by Western blotting
(Figure 5B). However, transduction with the control scramble
shRNA failed to reduce Syk expression in B/TSM cells (Figure 5B).
To determine if the transcriptional activation of chemokine
Figure 2. FceRI-a protein expression (24, 72 h) is upregulated by proinflammatory and Th-2 cytokines. Two-day serum-deprived
primary B/TSM cells were cultured in presence or absence of IL-1b, TNF-a or IL-4. FceRI-a protein from (A) 24 h and (B) 72 h culture cell lysates was
Immunoprecipitated (IP) followed by Western blotting, as described in Materials and Methods section. FceRI-a protein was immunoprecipitated with
either anti-FceRIa mAb 15/1 or with isotype antibody mouse IgG1 (MOPC21) for negative control. Non-specific bands from the same gels were used
as loading control. (C) FceRI-c protein was analyzed by Western blotting and (D) presented as the ratio of 9 KDa FceRI-c-specific protein bands
intensity over GAPDH (as internal control). Human basophilic KU812 cells were used as a positive control. Figures represent three separate
experiments. ns, non-significant (p.0.05).
doi:10.1371/journal.pone.0006153.g002
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silenced B/TSM cells were transiently transfected with wild-type
promoters for earlier studied CC and CXC chemokines and
stimulated with IgE, IL-1b, mIgG1 or left unstimulated. As shown
in Figure 5C, D, E and F, IgE-induced chemokines promoter
activity over unstimulated control was completely abrogated
(eotaxin-1/CCL11, 1.3060.01 to 0.9460.14-fold; IL-8/CXCL8,
1.2160.01 to 1.0860.07-fold; IP-10/CXCL10, 1.2260.01 to
1.0160.07-fold, and RANTES/CCL5, 1.3160.02 to 0.9460.09-
fold) in Syk-shRNA-transduced compared to the scramble-shRNA-
transduced B/TSM cells. However, in contrast, lentivirus-mediated
Syk-silencing in B/TSM cells did not affect the IL-1b-induced
promoteractivityforIL-8/CXCL8andIP-10/CXCL10(Figure5D
and E). Moreover, although eotaxin-1/CCL11 and RANTES/
CCL5promoteractivitywasslightlydecreased,itwasstillsignificant
compared to the unstimulated control in IL-1b-stimulated Syk-
silenced B/TSM cells (Figure 5C and F). The isotype mIgG1
(MOPC21) stimulation did not affect the promoter activity for any
of the chemokines in either Syk-shRNA or scramble-shRNA–
transduced B/TSM cells (Figure 5). Taken together, these results
suggest that the IgE-sensitization of B/TSM cells induce the
chemokine expression at least via involving Syk activity and the
respective chemokine promoter activation.
Discussion
Several studies have investigated the regulation of high affinity
IgE receptor (FceRI) expression in inflammatory cells both in vivo
and in vitro, and a correlation has been established between the
serum IgE levels and the FceRI expression on cell surface [28,29].
However, IgE is not the only factor governing FceRI expression,
since mast cells from IgE-deficient (IgE
2/2) mice express low
levels of FceRI [30]. Therefore, it is indeed apparent that the basal
FceRI expression is under the control of some other regulatory
mechanisms. Moreover, although the ASM cells were recently
shown to respond to IgE through the expression of a tetrameric
FceRI complex (abc2) [15], factors that modulate the FceRI
expression by ASM remain unknown.
Figure 3. TNF-a pre-sensitization augments multiple CC and CXC chemokines release following IgE stimulation. Primary human B/TSM
cells were cultured in presence of 10 ng/ml each of TNF-a, IL-1b, or IL-4 for 48 h. Cells were then washed twice, and stimulated with either IgE (1 mg/
ml), mIgG1-MOPC21 (1 mg/ml) or left unstimulated (medium alone) for another 24 h. Culture supernatants were used for (A) eotaxin-1/CCL11, (B) IL-8/
CXCL8, (C) IP-10/CXCL10, and (D) RANTES/CCL5 measurement by ELISA. Data represents mean6SD of three independent experiments performed
under the same conditions. Mann-Whitney U test was performed to analyze the differences between the samples. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0006153.g003
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(TNF-a) and Th2 (IL-4) cytokines upregulate the FceRI-a
expression in cultured human B/TSM cells both at transcript
and protein level. This was strikingly a novel finding as despite
being central proinflammatory mediators in allergic inflammation
[10,11,12,13], TNF-a and IL-1b have not previously been
investigated in the context of FceRI modulation in any cell type.
Interestingly, IgE engagement of FceRI on TNF-a pre-sensitized
B/TSM cells significantly augmented the eotaxin-1/CCL11, IL-
8/CXCL8, IP-10/CXCL10, and RANTES/CCL5 but not
TARC/CCL17 release. In addition, IgE sensitization of B/TSM
cells induced the gene expression for eotaxin-1/CCL11, IL-8/
CXCL8, IP-10/CXCL10, and RANTES/CCL5 at promoter
level, which was completely abrogated upon Lentivirus-mediated
Syk silencing. Our data underline the fact that proinflammatory
and Th2 cytokine-induced FceRI regulation in B/TSM cells could
significantly contribute to the airway inflammation via potentially
novel mechanisms involving IgE/FceRI complex.
TNF-a is a prototype proinflammatory cytokine which has been
proposed to exert deleterious effects directly on airway smooth
muscle, including its most recently explored roles in (i) activation of
transient receptor potential channel 3 (TRPC3) leading to
abnormal store-operated calcium influx, and (ii) upregulation of
CD38 which regulates intracellular calcium and plays a role in
airway hyperresponsiveness [31,32]. Both TNF-a and IL-1b,
independently, are known to induce IL-8/CXCL8 and
RANTES/CCL5 release in ASM [33]. IL-8/CXCL8 is a
chemoattractant for neutrophils, eosinophils, and to a lesser
extent, T-lymphocytes, while RANTES/CCL5 acts as a chemoat-
tractant for T-cell, eosinophils and monocytes. TNF-a also
induced the release of IP-10/CXCL-10, a potent chemokine for
activated T cells, NK cells and mast cells; and its expression is
differentially modulated by vitamin D in human ASM cells [34].
In the present study, TNF-a stimulation augmented both FceRI-a
transcript and protein expression in B/TSM cells. Of note, we did
not incubate the cultured B/TSM cells with cytokines and IgE
simultaneously as it could mask the effect of IgE. Indeed, we first
pre-sensitized the B/TSM cells with cytokines and then engaged
the receptor with IgE stimulation. Interestingly, TNF-a pre-
sensitization (and thus FceRI upregulation) followed by IgE
stimulation augmented the selective eotaxin-1/CCL11, IL-8/
CXCL8, IP-10/CXCL10, and RANTES/CCL5 chemokines
release, compared to IgE non-stimulated control. This was quite
a plausible observation at functional level since IgE could engage
the TNF-upregulated FceRI by a higher magnitude than basal
FceRI expressed on B/TSM cells. Surprisingly, IL-1b enhanced
the FceRI-a mRNA expression and had slight but not significant
effect on FceRI-a protein upregulation. In accordance with this,
IgE stimulation following IL-1b pre-sensitization did not augment
the chemokine release compared to IgE-unstimulated cells. This
may be explained by the involvement of post-transcriptional
regulatory mechanisms in FceRI protein expression in response to
IL-1b stimulation, and thus low magnitude of IgE-mediated
signaling. Taken together, our observations essentially provide
another mechanism by which TNF-a contribute to airway
inflammation, mainly amplifying the FceRI-mediated ASM
activation, and ultimately recruiting inflammatory cells through
multiple chemokine expression in airways.
FceRI-c chain was shown to be downregulated alongwith
FceRI-a chain by TGF-b1 in bone marrow derived mast cells
(BMMC) [35], and has been demonstrated to be the limiting factor
governing FceRIa surface expression in dendritic cells (DCs) [36].
However, we found that only FceRI-c transcript but not protein
was upregulated by TNF-a. Lack of FceRI-c protein upregulation
by TNF, IL-1b or IL-4 may suggest some post-transcriptional
regulatory mechanisms modulating the FceRI-c protein transla-
tion. Since B/TSM express all FceRI subunits (abc2) [15],
possibility of different regulatory mechanisms in B/TSM FceRI
Figure 4. IgE-sensitization induces the chemokines promoter activity in human B/TSM cells. Cultured human B/TSM cells were transiently
transfected with luciferase reporter constructs driven by wild-type promoters for human eotaxin-1/CCL11, IL-8/CXCL8, IP-10/CXCL10, and RANTES/
CCL5; stimulated with mIgG1-MOPC21, IgE, or IL-1b; and respective chemokine promoter activity was measured as mentioned in Materials and
Methods. Data were normalized according to the Renilla luciferase activity, and presented as fold-increase over unstimulated control. Data represents
the mean6SD of three separate experiments. Mann-Whitney U test was performed to analyze the differences between the samples. *P,0.05,
**P,0.01 compared to unstimulated control.
doi:10.1371/journal.pone.0006153.g004
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PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6153Figure 5. Lentivirus-mediated Syk shutdown abrogates the IgE-induced chemokines promoter activity in human B/TSM cells.
Human B/TSM cells were first transduced with a pseudotyped Lentiviral vector expressing specific Syk-shRNA or a non-specific scramble-shRNA. (A)
The Lentiviral transduction efficiency was more than 95% for both scramble-shRNA and Syk-shRNA as determined by FACS using the tGFP as the
marker for cell sorting. (B) Lentiviral Syk-shRNA transduction in B/TSM cells silenced the Syk expression efficiently as observed by Western blotting.
Syk- and scramble-transduced human B/TSM cells were then transiently transfected with luciferase reporter constructs driven by wild-type promoters
for human (C) eotaxin-1/CCL11, (D) IL-8/CXCL8, (E) IP-10/CXCL10, or (F) RANTES/CCL5; stimulated with mIgG1-MOPC21, IgE, or IL-1b for 12 h; and
respective chemokine promoter activity was measured as mentioned in Materials and Methods. Data were normalized according to the Renilla
luciferase activity, and presented as fold-increase over unstimulated control. Data represents the mean6SD of three separate experiments. Mann-
Whitney U test was performed to analyze the differences between the samples. *P,0.05, **P,0.01 compared to unstimulated control.
doi:10.1371/journal.pone.0006153.g005
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FceRI-c chain is also shared by Fc gamma receptor subtypes
expressed by B/TSM [37], additional regulatory mechanisms may
be in force in controlling FceRI-c expression. Detailed studies are
therefore required to delineate the regulation and role of FcRc in
amplification or stabilization, if any, of FceRI surface expression in
B/TSM cells.
IL-4 on the other hand, is a prototype Th2 cytokine which in
combination with IL-13, induce the class switch-recombination
from IgG to IgE by B-cells [6]. IL-4 plays a critical role in atopic
diseases and is also known to cause a marked increase in eotaxin-
1/CCL11 release in ASM cells [38,39]. In our present study,
interestingly, we found that IL-4 significantly enhances the surface
and intracellular FceRI-a protein expression in B/TSM cells. This
was quite interesting as there is a steady-state FceRI-a mRNA
expression under IL-4 stimulation, suggesting the coherent
translation of FceRI-a transcript into the protein at 24 h, 72 h
after stimulation (Figure 1B, 2A and B). Our data, therefore,
strongly supports the previously observed positive role of IL-4 in
the transcription of FceRIa-chain in human mast cells, eosinophils
from atopic dermatitis patients, human dendritic cells, and human
neutrophils [8,40,41,42].
Classical paradigm entails the IgE binding to FceRI as a ‘passive
sensitization’ step in the mast cell activation and requires the
multivalent antigens for cross-linking of FceRI-bound IgE [7].
However, recent reports highlight the IgE-mediated spectrum of
effects including the pro-survival effects on mast cells, monocytes,
and asthmatic neutrophils through binding to FceRI
[43,44,45,46]. Moreover, IgE alone (i.e. sensitization) induced
the expression of multiple cytokines (e.g. IL-6, TNF-a, IL-4 and
IL-13) and activated signaling pathways by phosphorylation of
several kinases such as Erks, p38, JNK and PKB in normal murine
BMMC [44]. In this line, after exploring the FceRI regulation by
proinflammatory and Th-2 cytokines and subsequent IgE-
mediated B/TSM activation, we tested our hypothesis of effect
of IgE sensitization alone on ASM synthetic function. Interesting-
ly, we found that IgE sensitization induces multiple, selective CC
(eotaxin-1/CCL11, RANTES/CCL5) and CXC (IL-8/CXCL8,
IP-10/CXCL10) chemokines expression in B/TSM cells at least at
promoter level.
In inflammatory cells, activation of Syk is crucial for IgE cross-
linking-induced FceRI downstream signals propagation including
phosphorylation of phospholipase Cc, calcium mobilization, and
degranulation [7,26]. Although details still remain to be
investigated, the initial signaling events in non cross-linking model
(i.e. IgE sensitization alone) of FceRI activation include the
activation of Lyn and Syk leading to the activation of ERK in mast
cells [47,48]. Interestingly, in our study, lentivirus-mediated Syk
shutdown in B/TSM cells completely abrogated the CC and CXC
chemokine promoter activity, suggesting the involvement and
requirement of Syk activity in IgE sensitization-induced chemo-
kine expression. These results essentially provide a proof-of-
principle and increase our understanding that at least initial
signaling events of IgE sensitization-induced FceRI activation are
similar, if not the same, in ASM and mast cells. Altogether, our
data suggest that blocking or silencing Syk, among others, could
present a useful therapeutic strategy for allergic inflammatory
disorders.
Collectively, our data demonstrate that proinflammatory (TNF-
a) and Th2 (IL-4) cytokines modulate the FceRI expression in B/
TSM, which can further augment the selective CC and CXC
chemokine release following IgE exposure. Moreover, IgE
sensitization of B/TSM cells induces multiple chemokine gene
expression, via involving at least Syk activity and the respective
gene promoter activation. Our data, therefore, highlight the fact
that proinflammatory and Th2 cytokines directly or indirectly
manifest the allergic inflammation, also by regulating FceRI
expression, hence amplifying the IgE/FceRI associated reactions.
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